PMC:7281546 / 832-1058 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T2","span":{"begin":86,"end":89},"obj":"Body_part"},{"id":"T3","span":{"begin":121,"end":124},"obj":"Body_part"}],"attributes":[{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma67095"}],"text":"1) encoding IFN antagonists to disrupt innate immune pathway, and 2) hiding its viral RNA to avoid the exposure of viral RNA to immune sensors. This review highlights the immune evasion mechanisms employed by PEDV, which provi"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T3","span":{"begin":12,"end":15},"obj":"Chemical"},{"id":"T4","span":{"begin":16,"end":27},"obj":"Chemical"}],"attributes":[{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_48706"}],"text":"1) encoding IFN antagonists to disrupt innate immune pathway, and 2) hiding its viral RNA to avoid the exposure of viral RNA to immune sensors. This review highlights the immune evasion mechanisms employed by PEDV, which provi"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T9","span":{"begin":39,"end":52},"obj":"http://purl.obolibrary.org/obo/GO_0045087"},{"id":"T10","span":{"begin":171,"end":185},"obj":"http://purl.obolibrary.org/obo/GO_0042783"}],"text":"1) encoding IFN antagonists to disrupt innate immune pathway, and 2) hiding its viral RNA to avoid the exposure of viral RNA to immune sensors. This review highlights the immune evasion mechanisms employed by PEDV, which provi"}

{"project":"LitCovid-sentences","denotations":[{"id":"T8","span":{"begin":0,"end":143},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"1) encoding IFN antagonists to disrupt innate immune pathway, and 2) hiding its viral RNA to avoid the exposure of viral RNA to immune sensors. This review highlights the immune evasion mechanisms employed by PEDV, which provi"}

{"project":"LitCovid-PubTator","denotations":[{"id":"20","span":{"begin":12,"end":15},"obj":"Gene"},{"id":"29","span":{"begin":209,"end":213},"obj":"Species"}],"attributes":[{"id":"A20","pred":"tao:has_database_id","subj":"20","obj":"Gene:3439"},{"id":"A29","pred":"tao:has_database_id","subj":"29","obj":"Tax:28295"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"1) encoding IFN antagonists to disrupt innate immune pathway, and 2) hiding its viral RNA to avoid the exposure of viral RNA to immune sensors. This review highlights the immune evasion mechanisms employed by PEDV, which provi"}